Related Experiment Videos

Torcetrapib/atorvastatin combination therapy

Harold Bays1, James McKenney, Michael Davidson

  • 1L-MARC Research Center, 3288 Illinois Avenue, Louisville, KY 40213, USA. HBays@aol.com

Expert Review of Cardiovascular Therapy
|September 27, 2005
PubMed

Insights

Combining atorvastatin and torcetrapib offers improved lipid profiles for reducing coronary heart disease (CHD) risk. This novel combination therapy targets both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol for enhanced cardiovascular protection.

Area of Science:

  • Cardiovascular Pharmacology
  • Lipid Metabolism
  • Drug Development

Background:

  • Elevated low-density lipoprotein cholesterol (LDL-C) significantly increases atherosclerotic coronary heart disease (CHD) risk.
  • Atorvastatin, a statin, effectively lowers LDL-C but offers limited CHD risk reduction alone.
  • Low high-density lipoprotein cholesterol (HDL-C) levels are also linked to increased CHD risk.

Purpose of the Study:

  • To review the combination agent torcetrapib/atorvastatin for complementary lipid benefits.
  • To evaluate the potential of this combination to reduce CHD risk beyond atorvastatin monotherapy.
  • To examine the chemistry, mechanism of action, pharmacokinetics, metabolism, safety, and efficacy of the combined agent.

Main Methods:

  • Review of existing literature on atorvastatin and torcetrapib.
  • Analysis of preclinical and clinical data for the combination therapy.
  • Examination of lipid-modifying actions and cardiovascular outcomes.

Main Results:

  • Torcetrapib, a cholesteryl ester transfer protein inhibitor, primarily raises HDL-C.
  • The combination of atorvastatin and torcetrapib demonstrates significant improvements in lipid profiles.
  • Complementary actions on LDL-C and HDL-C suggest enhanced efficacy for CHD risk reduction.

Conclusions:

  • The combination of torcetrapib and atorvastatin offers synergistic lipid-modifying effects.
  • This dual-action agent holds promise for achieving greater CHD risk reduction than atorvastatin alone.
  • Further development and evaluation of this combination therapy are warranted.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications